MarketCap
Facebook
X
TelegramQuartalsbericht 2025-Q3
hinzugefügt 31.01.2026
Autolus Therapeutics plc Langfristige Verbindlichkeiten 2011-2026 | AUTL
Langfristige Verbindlichkeiten Jährlich Autolus Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 50.6 M | 23.7 M | 601 K | 1.03 M | 758 K | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 50.6 M | 601 K | 15.3 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M |  USA |
 |
Amgen
AMGN
|
37.2 B | $ 341.88 | - | $ 184 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
182 M | $ 81.85 | -0.18 % | $ 1.58 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
686 M | $ 69.33 | - | $ 9.27 B | USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.6 | - | $ 16.3 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Adagene
ADAG
|
158 M | $ 2.75 | -5.5 % | $ 155 M | China |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.17 | -2.76 % | $ 7.63 B |  Australia |
 |
Biogen
BIIB
|
9.03 B | $ 179.89 | - | $ 26.2 B | USA |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
10.2 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
168 M | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
10.2 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
101 M | $ 226.1 | 0.96 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 113.75 | - | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
876 K | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
23.6 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
146 K | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
2.42 B | $ 13.68 | - | $ 4.23 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.63 M | $ 4.01 | -2.2 % | $ 8.73 B |  Israel |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
44.7 M | $ 6.58 | -1.35 % | $ 1.36 B | USA |
 |
Alpine Immune Sciences
ALPN
|
15.9 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Beam Therapeutics
BEAM
|
26 M | $ 27.62 | - | $ 2.27 B | USA |
 |
BeiGene, Ltd.
BGNE
|
374 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
30.8 B | $ 92.77 | 0.19 % | $ 96.9 B | Britain |